Navin Fluorine International
Navin Fluorine International
ChemicalsKey Fundamentals
MidcapSpecialty ChemicalsChemicalsTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is expected to give good quarter
- Company has delivered good profit growth of 21.4% CAGR over last 5 years
Weaknesses
1- Stock is trading at 11.0 times its book value
Growth Rate
AI Analysis — Bull vs Bear
Navin Fluorine International, with a market cap of ₹44,148 Cr, is a specialty chemicals company that has delivered TTM sales growth of 42% and TTM profit growth of 124%. The stock trades at a PE of 56.5x and 11.2x price-to-book, reflecting premium valuations, while its last-year ROE of 20% marks an improvement over its 5-year average of 15%.
- TTM revenue growth of 42% is significantly above the 10-year compounded sales CAGR of 17%, indicating a sharp acceleration in business momentum
- TTM profit growth of 124% demonstrates strong operating leverage and margin expansion over the trailing twelve months
- Last-year ROE of 20% is the highest in the reported series, up from the 5-year average of 15% and 10-year average of 17%, signalling improving capital efficiency
- Compounded profit CAGR of 21% over 5 years outpaces the compounded sales CAGR of 23% over the same period, indicating consistent earnings quality
- 10-year stock CAGR of 34% reflects sustained long-term wealth creation for shareholders over a full market cycle
- Company is expected to deliver a good upcoming quarter, suggesting near-term earnings visibility remains intact
- 10-year compounded sales CAGR of 17% points to a durable structural growth trajectory in the fluorine chemicals space
- PE ratio of 56.5x is significantly elevated compared to broader market averages, leaving limited margin of safety if growth decelerates
- Price-to-book ratio of 11.2x is extremely high, meaning the stock prices in substantial future growth and any disappointment could lead to sharp de-rating
- Dividend yield of just 0.17% offers negligible income return, making the stock entirely dependent on capital appreciation
- 1-year stock CAGR of 83% has far outpaced the TTM profit growth of 124% in percentage terms but raises the risk of mean reversion if earnings momentum slows
- 3-year compounded sales CAGR of 17% is well below the TTM rate of 42%, raising the question of whether the recent acceleration is sustainable or one-off
- ROE and ROCE data points are reported as unavailable for current period, limiting full visibility into current return-on-capital efficiency and balance sheet health
- Debt-to-equity ratio is not available in reported metrics, making it difficult to assess financial leverage and balance sheet risk
- 52-week high and low data are reported as zero, limiting technical context on where the stock trades relative to its recent range
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Q1FY27 profit surges 108% YoY Sep 7
Navin Fluorine reported Q1FY27 consolidated net profit of ₹243.3 crore, up 108% YoY, with revenue rising 44% to ₹1,045.1 crore driven by strong volume growth and margin expansion across HPP, Specialty Chemicals, and CDMO segments.
TL;DR: Navin Fluorine delivered a standout Q1FY27 with profit more than doubling and broad-based growth across all key segments including HPP, Specialty Chemicals, and CDMO. No visible headwinds emerged from recent coverage. The strong volume-driven momentum and margin expansion suggest an improving trend, though sustaining this growth rate will depend on continued demand in fluorine specialty markets.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 491 | 472 | 500 | 602 | 524 | 519 | 606 | 701 | 725 | 758 | 892 | 938 | 1,045 |
| Expenses | 377 | 373 | 424 | 492 | 423 | 411 | 459 | 522 | 519 | 512 | 585 | 617 | 688 |
| Operating Profit | 114 | 98 | 76 | 110 | 100 | 107 | 147 | 179 | 207 | 246 | 308 | 321 | 357 |
| OPM % | 23% | 21% | 15% | 18% | 19% | 21% | 24% | 26% | 29% | 32% | 34% | 34% | 34% |
| Other Income | 8 | 23 | 64 | 13 | 10 | 11 | 10 | 12 | 14 | 18 | -5 | 31 | 35 |
| Interest | 19 | 20 | 18 | 17 | 16 | 14 | 20 | 28 | 30 | 30 | 28 | 29 | 32 |
| Depreciation | 21 | 24 | 25 | 26 | 27 | 28 | 30 | 35 | 35 | 37 | 36 | 41 | 42 |
| PBT | 82 | 77 | 97 | 79 | 68 | 77 | 108 | 127 | 155 | 198 | 238 | 282 | 318 |
| Tax % | 25% | 22% | 20% | 11% | 25% | 23% | 23% | 25% | 24% | 25% | 22% | 25% | 24% |
| Net Profit | 62 | 61 | 78 | 70 | 51 | 59 | 84 | 95 | 117 | 148 | 185 | 213 | 243 |
| EPS in Rs | 12.41 | 12.22 | 15.74 | 14.19 | 10.32 | 11.86 | 16.86 | 19.15 | 23.62 | 28.96 | 36.18 | 41.48 | 47.43 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 592 | 680 | 742 | 913 | 996 | 1,062 | 1,179 | 1,453 | 2,077 | 2,065 | 2,349 | 3,314 | 3,634 |
| Expenses | 519 | 561 | 582 | 693 | 777 | 794 | 870 | 1,098 | 1,527 | 1,666 | 1,816 | 2,232 | 2,402 |
| Operating Profit | 72 | 118 | 159 | 220 | 219 | 268 | 309 | 356 | 550 | 399 | 534 | 1,082 | 1,232 |
| OPM % | 12% | 17% | 21% | 24% | 22% | 25% | 26% | 24% | 26% | 19% | 23% | 33% | 34% |
| Other Income | 29 | 23 | 55 | 88 | 34 | 29 | 94 | 38 | 36 | 107 | 44 | 58 | 80 |
| Interest | 3 | 4 | 3 | 1 | 1 | 2 | 2 | 2 | 28 | 75 | 78 | 118 | 120 |
| Depreciation | 20 | 22 | 30 | 40 | 28 | 37 | 44 | 48 | 63 | 96 | 119 | 149 | 156 |
| PBT | 78 | 116 | 182 | 266 | 224 | 258 | 358 | 344 | 496 | 336 | 380 | 873 | 1,036 |
| Tax % | 26% | 28% | 25% | 32% | 34% | -56% | 31% | 24% | 24% | 19% | 24% | 24% | — |
| Net Profit | 58 | 84 | 137 | 180 | 149 | 409 | 258 | 263 | 375 | 270 | 289 | 664 | 790 |
| EPS in Rs | 11.18 | 17.08 | 27.88 | 36.43 | 30.15 | 82.57 | 52.02 | 53.09 | 75.68 | 54.56 | 58.19 | 129 | 154 |
| Div. Payout % | 29% | 25% | 23% | 27% | 26% | 13% | 21% | 21% | 16% | 27% | 12% | 7% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 578 | 636 | 825 | 974 | 1,063 | 1,402 | 1,624 | 1,834 | 2,175 | 2,373 | 2,616 | 3,964 |
| Borrowings | 61 | 82 | 19 | 13 | 4 | 1 | 25 | 121 | 861 | 1,368 | 1,466 | 1,272 |
| Other Liabilities | 203 | 228 | 324 | 259 | 231 | 215 | 239 | 420 | 484 | 626 | 738 | 1,133 |
| Total Liabilities | 852 | 955 | 1,177 | 1,256 | 1,307 | 1,629 | 1,898 | 2,385 | 3,529 | 4,377 | 4,830 | 6,379 |
| Fixed Assets | 274 | 375 | 561 | 428 | 430 | 529 | 540 | 556 | 1,646 | 1,875 | 2,736 | 3,324 |
| CWIP | 60 | 20 | 17 | 20 | 39 | 39 | 95 | 742 | 279 | 711 | 355 | 143 |
| Investments | 171 | 170 | 239 | 428 | 427 | 195 | 99 | 118 | 44 | 495 | 480 | 1,229 |
| Other Assets | 346 | 390 | 360 | 380 | 410 | 866 | 1,163 | 969 | 1,561 | 1,296 | 1,259 | 1,683 |
| Total Assets | 852 | 955 | 1,177 | 1,256 | 1,307 | 1,629 | 1,898 | 2,385 | 3,529 | 4,377 | 4,830 | 6,379 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1 | 76 | 92 | 169 | 90 | 157 | 237 | 75 | -64 | 750 | 571 | 894 |
| Investing | 3 | -53 | -16 | -136 | -24 | 85 | -237 | -172 | -656 | -1,094 | -511 | -1,235 |
| Financing | -21 | -17 | -67 | -39 | -68 | -81 | -45 | 42 | 658 | 336 | -47 | 344 |
| Net Cash Flow | -17 | 6 | 10 | -6 | -3 | 161 | -45 | -56 | -61 | -8 | 13 | 3 |
| Free Cash Flow | -61 | 58 | -84 | 121 | 29 | 59 | 147 | -501 | -819 | 72 | 4 | 404 |
| CFO/OP | 28 | 87 | 78 | 100 | 74 | 76 | 71 | 43 | 8 | 196 | 122 | 97 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 81 | 68 | 62 | 63 | 75 | 88 | 90 | 99 | 91 | 90 | 83 |
| Inventory Days | 96 | 89 | 136 | 110 | 91 | 127 | 129 | 149 | 197 | 150 | 117 | 121 |
| Days Payable | 113 | 112 | 94 | 92 | 58 | 79 | 77 | 85 | 103 | 122 | 118 | 144 |
| Cash Conversion Cycle | 57 | 57 | 110 | 80 | 96 | 123 | 140 | 154 | 193 | 119 | 89 | 60 |
| Working Capital Days | 39 | 37 | 4 | 43 | 58 | 88 | 113 | 109 | 140 | 45 | 25 | 44 |
| ROCE % | 11% | 17% | 22% | 29% | 21% | 21% | 22% | 19% | 20% | 11% | 11% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Navin Fluorine International insights
64 extracted metrics + investor summaries across FY00–FY27.
Documents
Frequently Asked Questions about Navin Fluorine International
What does Navin Fluorine International Ltd do?
Where is Navin Fluorine International Ltd (NAVINFLUOR) listed?
Which sector does Navin Fluorine International Ltd belong to?
What is the market capitalisation of Navin Fluorine International Ltd?
What is the PE ratio of Navin Fluorine International Ltd?
What is the 52-week high and low of Navin Fluorine International Ltd?
Does Navin Fluorine International Ltd pay dividends?
What is the Return on Equity (ROE) of Navin Fluorine International Ltd?
Company Information
Navin Fluorine International Ltd is primary engaged in producing refrigeration gases, inorganic fluorides, specialty organofluorines and offers contract research and manufacturing services.[1] Its portfolio includes 50+ fluorinated compounds developed over the years.[2]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NAVINFLUOR.md for Navin Fluorine International Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.